Akebia Therapeutics Inc(AKBA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:33 PM ET (Korea 9/12 08:33)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.11 | Insider Own | 2.8% | Shs Outstand | 271.7M | Perf Week | -2.9% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | -117.86% | Insider Trans | -0.72% | Shs Float | 269.3M | Perf Month | 6.9% |
| Enterprise Value | 0.32B | PEG | - | EPS next Q | -0.04 | Inst Own | 40.56% | Short Float | 8.54% | Perf Quarter | 6.16% |
| Income | -0.03B | P/S | 1.21 | EPS this Y | -600% | Inst Trans | 2.88% | Short Ratio | 3.67 | Perf Half Y | -31.8% |
| Sales | 0.22B | P/B | 10.37 | EPS next 5Y | - | ROA | -8.53% | Short Interest | 23.00M | Perf YTD | -40.7% |
| Book/sh | 0.09 | P/C | 1.68 | EPS past 3/5Y | 65.7% 62.4% | ROE | -109.38% | 52W High | -70.16% ($3.20) | Perf Year | -68.07% |
| Cash/sh | 0.57 | P/FCF | 6.57 | Sales past 3/5Y | -6.88% -4.37% | ROIC | -15.93% | 52W Low | 17.3% ($0.81) | Perf 3Y | -26.55% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 35.69% | Gross Margin | 78.92% | Volatility(W/M) | 6.32% 6.38% | Perf 5Y | -66.85% |
| Dividend TTM | - | EV/Sales | 1.45 | Sales Y/Y TTM | 7.52% | Oper. Margin | -6.02% | ATR (14) | 0.06 | Perf 10Y | -88.47% |
| Dividend Ex-Date | - | Quick Ratio | 1.35 | EPS Q/Q | -3766.67% | Profit Margin | -13.54% | RSI (14) | 46.53 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.43 | Sales Q/Q | -21.36% | SMA20 | 2.85% ($0.92) | Beta | 0.18 | Target Price | $3.92 |
| Payout | - | Debt/Eq | 8.43 | Earnings | 2026/8/5 | SMA50 | -14.19% ($1.11) | Rel Volume | 0.98 | Prev Close | $0.95 |
| Employees | 194 | LT Debt/Eq | 6.44 | EPS/Sales Surpr. | 28.57% 0.56% | SMA200 | -25.49% ($1.27) | Avg Volume(3M) | 6.26M | Price | $0.95 |
| IPO | 2014/3/20 | Option/Short | Yes/Yes | Trades | 8636 | Volume | 6,140,386 | Change | 0.88% |
Company
AKBA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩺 This is a US biopharmaceutical company specializing in kidney diseases, primarily focused on anemia treatments for patients with chronic kidney disease. The company has commercialized Vafseo (vadadustat), an oral anemia treatment for dialysis patients, and Auryxia (ferric citrate), a phosphate binder. It is a specialty and generic pharmaceutical company that is expanding its pipeline for rare kidney diseases.
Over the past 1 year, on the lower side
70% below its 1-year high.
AKBA has weak earning power
Review management risk carefully before investing
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -600.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -26.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 40.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
QQQS 0.00%
SBIO 0.00%
SQLV 0.00%
XBI 0.00%
LABU 0.00%It ranks #4 in the industry
Based on market cap of $265M.
AKBA $265M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is AKBA?
AKBA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AKBA?
The market cap of AKBA is approximately $265M, ranking 3,871 within its sector.
What is the 52-week high and low for AKBA?
AKBA has recorded a 52-week high of $3.20 and a low of $0.81.
